Quarterly ResultMay 6, 2026, 04:42 PM
DiaMedica Therapeutics Q1 Net Loss $10.0M; ReMEDy2 Trial 70% Enrolled
AI Summary
DiaMedica Therapeutics reported a net loss of $10.0 million for the first quarter ended March 31, 2026, an increase from $7.7 million in Q1 2025, primarily due to higher R&D expenses of $8.0 million. The company's cash, cash equivalents, and investments stood at $51.3 million, providing an anticipated runway through 2027. Operationally, the ReMEDy2 Phase 2/3 Acute Ischemic Stroke trial of DM199 has surpassed 70% interim enrollment, with an interim analysis planned for Q4 2026, and the Preeclampsia Phase 2 IST Part 1a expansion cohort is enrolling with data expected in Q2 2026.
Key Highlights
- ReMEDy2 Phase 2/3 AIS trial surpassed 70% interim enrollment; interim analysis planned 4Q 2026.
- Cash, cash equivalents, and investments were $51.3 million as of March 31, 2026, with runway through 2027.
- Net loss was $10.0 million for Q1 2026, compared to $7.7 million for Q1 2025.
- R&D expenses increased to $8.0 million in Q1 2026 from $5.7 million in Q1 2025.
- Net cash used in operating activities was $9.1 million for Q1 2026, up from $7.1 million in Q1 2025.
- DM199 Preeclampsia Phase 2 IST Part 1a expansion cohort enrolling; updated dataset expected 2Q 2026.
- Early-Onset Preeclampsia Phase 2 trial in Canada anticipates first patient dosing before end of 2026.